SCHEMBL7226940

SCHEMBL7226940

CC(C)C1CN(c2c(F)cc3c(=O)c(C(=O)O)cn4c3c2CCC4C)CC[C@@H]1O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.74
KCNH2 Q12809 5/20 0.51
KDM4E B2RXH2 9/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CYP1A2 P05177 1/20 0.50
ALDH1A1 P00352 6/20 0.47
HPGD P15428 5/20 0.47
HSD17B10 Q99714 4/20 0.47
POLB P06746 3/20 0.47
OPRM1 P35372 2/20 0.47
CHRM2 P08172 1/20 0.47
CHRM1 P11229 1/20 0.47
OPRD1 P41143 1/20 0.47
ALB P02768 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
AADAT Q8N5Z0 2/20 0.47
TUBB4A P04350 1/20 0.47
TUBB P07437 1/20 0.47
TUBA3C P0DPH7 1/20 0.47
TUBA1B P68363 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7762057 0.89 LMNA (0.79) LMNAKCNH2KDM4ESMN1; SMN2CYP1A2
SCHEMBL4379656 0.89 LMNA (0.79) LMNAKCNH2KDM4ESMN1; SMN2CYP1A2
SCHEMBL4369351 0.89 LMNA (0.79) LMNAKCNH2KDM4ESMN1; SMN2CYP1A2
SCHEMBL4369898 0.89 LMNA (0.79) LMNAKCNH2KDM4ESMN1; SMN2CYP1A2
Water SCHEMBL7764910 0.89 LMNA (0.78) LMNAKCNH2KDM4ESMN1; SMN2CYP1A2
SCHEMBL7225048 0.89 LMNA (0.78) LMNAKCNH2KDM4ESMN1; SMN2CYP1A2
SCHEMBL7233027 0.88 LMNA (0.72) LMNAKCNH2KDM4ESMN1; SMN2CYP1A2
SCHEMBL7227115 0.87 LMNA (0.75) LMNAKCNH2KDM4ESMN1; SMN2CYP1A2
SCHEMBL6267713 0.86 LMNA (0.74) LMNAKCNH2KDM4ESMN1; SMN2CYP1A2
SCHEMBL6267719 0.86 LMNA (0.74) LMNAKCNH2KDM4ESMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608078-B2 Gramnegative bacteria WOCKHARDT LIMITED (IN) 2003-08-19 US claimed
US-20020165227-A1 Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment WOCKHARDT RESEARCH CENTER 2002-11-07 US claimed
US-6608078-B2 Gramnegative bacteria WOCKHARDT LIMITED (IN) 2003-08-19 US disclosed
US-20020165227-A1 Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment WOCKHARDT RESEARCH CENTER 2002-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165227-A1 Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment ALPI, POLR1C, POLI LMNA 1788/4885KCNH2 1639/4885KDM4E 2308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.